Psycheceutical, Inc (OTCMKTS:BWVI), which develops and commercializes psychedelic medicines, announced on May 10, 2022 about adding original Shark Tank entrepreneur Kevin Harrington as the corporation’s newest investor and strategic advisor. He has joined the company to offer advice regarding strategy, direction, and execution of the company’s growth and end goal to make more effective and safer psychedelic pharmaceutical medicines.
Trading Data
On Wednesday, BWVI stock slumped 26% to $0.2150 with more than 460K shares, compared to volume of 103K shares. The stock moved within a range of $0.1975 – 0.3590 after opening trade at $0.29.
Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor
Kevin Harrington is a well-known personality, from the hit TV show Shark Tank, the creator of the infomercial, and pioneer of the As Seen on TV brand. His business ventures are super successful, with over 1000 products being launched that have generated more than $6 billion in global sales. More than 20 of Harrington’s companies have each topped $100 million in revenue.
According to Harrington, it is high time that a different approach is used for mental health issues like depression, anxiety, or addiction. Psychedelic medicines have shown promising results, even where traditional drugs have failed. He has joined and invested in the company because of their patented next-generation delivery technologies, designed to increase the safety and efficacy of psychedelic compounds without the hallucinogenic side effects.
Chad Harman, CEO of Psycheceutical welcomes Kevin Harrington on board, and is confident that his passion for mental health, will take the company forward in terms of devising advanced psychedelic treatments to combat the mental health epidemic.
Key Quote
“The world is undergoing an unprecedented mental health crisis. We all know someone who is suffering from depression, anxiety, or addiction. What we’ve been doing isn’t working,” said Harrington.
Technical Data
BWVI stock is trading below the 20-Day and 50-Day Moving averages of $0.22 and $0.26 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.28.
